Korea Research Institute of Chemical Technology

Korea Research Institute of Bioscience and Biotechnology

Cj Corporation

Jeil Pharm. Co., Ltd.

Handok Pharmaceuticals Co., Ltd.

Jin Hee Ahn

Sang Dal Rhee

Won Hoon Jung

Seung Jun Kim

Seung Kyu Kang

Kwang-Rok Kim

Ki Young Kim

Sung Soo Kim

Hyae Gyeong Cheon

Jeong-Hyung Lee

Sung-eun Yoo

Jae Mok Lee

Jong Min Kim

Nam Gee Kim

Hwan Mook Kim

Sung Hoon Ahn

Sung Dae Park

Sung-Don Yang

Chang Woo Lee

Dae Gwin Jeong

Myung Ae Bae

Seog Beom Song

Myung-Ae Bae

Song Kyu Park

Seong Eon Ryu

Ki Ho Lee

Nam Sook Kang

Jin Sook Song

Joong-Kwon Choi

Sang Hyeup Lee

Hee Youn Kim

Hyun Jung Kwak

Hye Jung Kang

Suk Kyeong Jung

Jang Hyuk Lee

H S Pagire

Sun Mee Kim

Kil Woong Mo

Koun Ho Lee

Soon Ji Kwon

Sun Chul Huh

The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.

Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient

Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD1), and is useful in the treatment of various diseases that are mediated by 11&#x3b2;-HSD1. 

Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt

Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity thereof is modulated.

Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same

The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

Indene derivatives and process for the preparation thereof

An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, or phenyl; being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH, NO, OR, phenyloxy, Calkyl, and Ccycloalkyl; and

Growing community of inventors

Daejeon, South Korea

Jin Hee Ahn